JPWO2006038527A1 - Anti-tumor immunostimulant containing tamogi mushroom extract as active ingredient - Google Patents

Anti-tumor immunostimulant containing tamogi mushroom extract as active ingredient Download PDF

Info

Publication number
JPWO2006038527A1
JPWO2006038527A1 JP2006539248A JP2006539248A JPWO2006038527A1 JP WO2006038527 A1 JPWO2006038527 A1 JP WO2006038527A1 JP 2006539248 A JP2006539248 A JP 2006539248A JP 2006539248 A JP2006539248 A JP 2006539248A JP WO2006038527 A1 JPWO2006038527 A1 JP WO2006038527A1
Authority
JP
Japan
Prior art keywords
cells
extract
tumor
hot water
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006539248A
Other languages
Japanese (ja)
Inventor
吉成 篤四郎
篤四郎 吉成
和則 加藤
和則 加藤
Original Assignee
株式会社スリービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社スリービー filed Critical 株式会社スリービー
Publication of JPWO2006038527A1 publication Critical patent/JPWO2006038527A1/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Pulmonology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

たもぎ茸抽出物を有効成分とする抗腫瘍性免疫賦活剤が開示される。たもぎ茸抽出物は、腫瘍細胞細胞の増殖を抑制し、免疫賦活性サイトカインの産生を増強し、免疫抑制性T細胞増加を抑制することが示された。本発明はまた、たもぎ茸抽出物からなる免疫賦活用健康食品ならびに腫瘍細胞増殖抑制用健康食品を提供する。Disclosed is an antitumor immunostimulant containing a potato extract as an active ingredient. It has been shown that the bamboo shoot extract suppresses the growth of tumor cell cells, enhances the production of immunostimulatory cytokines, and suppresses the increase in immunosuppressive T cells. The present invention also provides an immune-stimulated health food comprising a bamboo shoot extract and a health food for suppressing tumor cell growth.

Description

本発明は、たもぎ茸抽出物を有効成分とする抗腫瘍性免疫賦活剤および免疫賦活用健康食品に関する。   The present invention relates to an antitumor immunostimulant and an immunostimulatory health food containing a potato extract as an active ingredient.

キノコ類の生体免疫賦活作用についてはさまざまな報告がされており、免疫賦活の機作やキノコ種の違いによる生理活性の差などが徐々に明らかにされている。これまでにある種のキノコ類に含有される多糖体が抗癌の目的で製品化され使用されているが、その効果は必ずしも充分なものとはいえず、より有用な免疫賦活剤が望まれていた。   Various reports have been made on the bioimmunity-stimulating action of mushrooms, and the mechanism of immunostimulation and the difference in physiological activity due to the difference in mushroom species have been gradually clarified. So far, polysaccharides contained in certain types of mushrooms have been commercialized and used for anti-cancer purposes, but their effects are not always sufficient, and more useful immunostimulators are desired. It was.

近年、各種感染症、癌などに対する薬剤による治療法が開発され、その有用性が見いだされているが、癌化学療法や癌免疫療法も満足すべき結果は得られていない。これら疾患の発症は免疫担当細胞類の活性低下に起因するところが大きい。このため、免疫担当細胞に対して免疫賦活効果を有する組成物は、これらの疾患の予防や治療に極めて有用であり、健康維持の観点からも重要である。   In recent years, therapeutic methods using drugs for various infectious diseases and cancers have been developed and their usefulness has been found, but satisfactory results have not been obtained for cancer chemotherapy and cancer immunotherapy. The onset of these diseases is largely due to decreased activity of immunocompetent cells. Therefore, a composition having an immunostimulatory effect on immunocompetent cells is extremely useful for the prevention and treatment of these diseases, and is also important from the viewpoint of maintaining health.

免疫系による生体防御機構には自然免疫と獲得免疫がある。自然免疫はマクロファージ、白血球が主体となり病原性細菌等のパターンを認識し捕食することにより生体内から排除する機構であるのに対して、獲得免疫はT細胞とB細胞を主体とした多様な異物抗原にそれぞれ対応できる免疫応答である。その免疫応答は抗原に生体が暴露されるほど強力かつ効率的に反応し、ウイルスなどの再感染を防御している。しかしながら免疫応答が生体内で常に活発に行われていると、逆に炎症性組織障害や自己免疫性疾患が多発することが示されており、生体内にはその免疫応答を“負”に制御できる細胞、つまり抑制性T細胞が正常個体中に自然状態で自己免疫寛容の維持に関与している。   The host defense mechanism by the immune system includes innate immunity and acquired immunity. Innate immunity is a mechanism in which macrophages and leukocytes are the main components that eliminate patterns from the living body by recognizing and preying on patterns of pathogenic bacteria, while acquired immunity is a variety of foreign substances mainly consisting of T cells and B cells. It is an immune response that can respond to each antigen. The immune response reacts as powerfully and efficiently as the living body is exposed to the antigen, and protects against reinfection of viruses and the like. However, it has been shown that inflammatory tissue damage and autoimmune diseases occur frequently when the immune response is constantly active in the body, and the immune response is negatively controlled in the body. Cells, i.e., suppressor T cells, are naturally involved in maintaining autoimmune tolerance in normal individuals.

最近の研究で自然状態に存在する抑制性T細胞の異常がヒトの自己免疫性疾患、炎症性腸炎、アレルギーの直接原因となることが示されている。この抑制性T細胞の機能を強化できれば自己免疫病やアレルギー、さらには移植臓器に対する免疫拒絶反応の制御も期待できる。   Recent studies have shown that abnormal suppressor T cells are a direct cause of human autoimmune diseases, inflammatory bowel disease, and allergies. If the function of this suppressor T cell can be strengthened, it can be expected to control autoimmune diseases, allergies, and immune rejection to transplanted organs.

一方、抑制性T細胞は正常個体中で自己から発生した腫瘍細胞(癌細胞)に対する有効な免疫反応を阻害していることが示されている。すなわち自己免疫寛容に関与する細胞が腫瘍細胞に対しても寛容であることが考えられる。実際に正常個体から抑制性T細胞を実験的に除去すると腫瘍に対する免疫応答が惹起あるいは強化され抗腫瘍効果が発揮できる。   On the other hand, it has been shown that inhibitory T cells inhibit an effective immune response against tumor cells (cancer cells) generated from self in normal individuals. That is, it is considered that cells involved in autoimmune tolerance are also tolerant to tumor cells. Actually, when inhibitory T cells are experimentally removed from a normal individual, an immune response to the tumor is induced or enhanced, and an antitumor effect can be exerted.

正常個体に存在する抑制性T細胞はCD4陽性T細胞群に含まれるCD25またはGITR(Glucocorticoid-induced TNFR family gene)およびFoxP3遺伝子陽性細胞として分類されている。そのため正常個体中のリンパ組織(脾臓、リンパ節、末梢血、骨髄)に存在する抑制性T細胞はCD4とCD25、GITRまたはFoxP3分子の発現陽性細胞で解析することが可能である。抑制性T細胞の割合が生体内で増加しているときは個体が免疫寛容もしくは免疫抑制状態に陥りやすく、腫瘍、ウイルス、病原性細菌等に対する免疫応答も低下する。   Inhibitory T cells present in normal individuals are classified as CD25 or GITR (Glucocorticoid-induced TNFR family gene) and FoxP3 gene positive cells contained in the CD4 positive T cell group. Therefore, inhibitory T cells present in lymphoid tissues (spleen, lymph nodes, peripheral blood, bone marrow) in normal individuals can be analyzed with CD4 and CD25, GITR or FoxP3 molecule-positive cells. When the ratio of inhibitory T cells is increased in vivo, the individual is likely to be immunotolerant or immunosuppressed, and the immune response against tumors, viruses, pathogenic bacteria, etc. is also reduced.

したがって、免疫抑制性T細胞の増加を抑制しうる免疫調整物質は免疫賦活剤の有効成分として有用であると考えられる。   Therefore, an immunomodulator that can suppress the increase of immunosuppressive T cells is considered useful as an active ingredient of an immunostimulator.

本発明に関連する先行技術文献情報としては以下のものがある:特開平11−302191、および三崎旭ら、「キシメジ科食用茸(ヒラタケ、タモギタケ)の多糖の化学的性質及び抗腫瘍作用」、大阪市立大学生活科学部紀要、第39巻(1991)、p.1−8。   Prior art document information relating to the present invention includes the following: JP-A-11-302191, and Asahi Misaki et al., “Chemical Properties and Antitumor Action of Polysaccharides of Edible Mushrooms, Oyster Mushrooms,” Bulletin of Osaka City University School of Life Sciences, Volume 39 (1991), p. 1-8.

本発明は、安全性が極めて高い、免疫賦活作用を有する薬剤ならびに機能性食品を提供することを目的とする。   An object of this invention is to provide the chemical | medical agent and functional food which have an extremely high safety | security and an immunostimulatory effect.

本発明者らは、北海道産の食用キノコから免疫賦活作用を有するキノコを検索した結果、たもぎ茸の抽出物に高い免疫賦活作用があることを見いだした。   As a result of searching for mushrooms having an immunostimulatory effect from edible mushrooms produced in Hokkaido, the present inventors have found that the extract of Tamogi mushroom has a high immunostimulatory effect.

すなわち、本発明は、たもぎ茸抽出物を有効成分とする抗腫瘍性免疫賦活剤を提供する。別の態様においては、本発明は、たもぎ茸抽出物を有効成分とする腫瘍細胞増殖抑制剤を提供する。腫瘍細胞としては、ヒトの体内の腫瘍、例えば、子宮頚部癌、白血病、リンパ腫、骨髄腫、黒色種、膵臓癌、前立腺癌、頭頚部癌、乳癌、肺癌、大腸癌、胃癌、食道癌、卵巣癌、扁平上皮癌、肝細胞癌、胆管癌、中皮腫および類表皮癌由来細胞、マウス等の実験動物に移植された腫瘍細胞、ならびにヒト腫瘍に由来する細胞株の細胞、例えば、HeLa、MeWo, Hs695T, A137, KATO-III, MKN45, MKN28, HuH28, Daudi, Ramos, Raji, U937, HS-Sultan, SKM-1, THP-1, IM-9, MM1S, K562, HL60, HSC-3, HSC-4, TTn, TE-10, IMR-32, U251, PC-3, LNCaP, DU145, DLD-1, WiDr, SW837, Lu135, IMR-90, A549, SK-OV-3, SK-Br-3, A431, RMG-1, MCF-7, MIAPaCa-2, AsPC1, KP-4が含まれる。また別の態様においては、本発明は、たもぎ茸抽出物を有効成分とする免疫賦活性サイトカインの産生の増強剤を提供する。免疫賦活性サイトカインとしては、例えば、インターロイキン(IL)1、2、3、4、5、6、7、12、15、18、21、23、インターフェロン(IFN)α、β、γ、腫瘍壊死因子(TNF)α、β、が挙げられる。また別の態様においては、本発明は、たもぎ茸抽出物を有効成分とする免疫抑制性T細胞増加の抑制剤を提供する。さらに別の態様においては、本発明は、たもぎ茸抽出物からなる免疫賦活用健康食品ならびに腫瘍細胞増殖抑制用健康食品を提供する。   That is, this invention provides the antitumor immunostimulant which uses a bamboo shoot extract as an active ingredient. In another aspect, the present invention provides a tumor cell growth inhibitor comprising a potato extract as an active ingredient. Tumor cells include tumors in the human body such as cervical cancer, leukemia, lymphoma, myeloma, melanoma, pancreatic cancer, prostate cancer, head and neck cancer, breast cancer, lung cancer, colon cancer, stomach cancer, esophageal cancer, ovary Cancer, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma and epidermoid carcinoma-derived cells, tumor cells transplanted into laboratory animals such as mice, and cells of cell lines derived from human tumors such as HeLa, MeWo, Hs695T, A137, KATO-III, MKN45, MKN28, HuH28, Daudi, Ramos, Raji, U937, HS-Sultan, SKM-1, THP-1, IM-9, MM1S, K562, HL60, HSC-3, HSC-4, TTn, TE-10, IMR-32, U251, PC-3, LNCaP, DU145, DLD-1, WiDr, SW837, Lu135, IMR-90, A549, SK-OV-3, SK-Br- 3, A431, RMG-1, MCF-7, MIAPaCa-2, AsPC1, KP-4. In another aspect, the present invention provides an agent for enhancing the production of immunostimulatory cytokines comprising a potato extract as an active ingredient. Examples of the immunostimulatory cytokine include interleukin (IL) 1, 2, 3, 4, 5, 6, 7, 12, 15, 18, 21, 23, interferon (IFN) α, β, γ, tumor necrosis Factors (TNF) α and β are mentioned. In another aspect, the present invention provides an inhibitor of immunosuppressive T cell increase comprising a potato extract as an active ingredient. In still another aspect, the present invention provides an immune-stimulating health food comprising a rice cake extract and a health food for suppressing tumor cell growth.

図1は、たもぎ茸熱水抽出物によるHeLa細胞増殖の抑制を示す。
図2は、たもぎ茸熱水抽出物による腫瘍細胞Sarcoma180の増殖の抑制を示す。
図3は、たもぎ茸熱水抽出物によるヒト樹状細胞の活性化抗原発現の増加を示す。
図4は、たもぎ茸熱水抽出物によるヒト樹状細胞からのIL−12産生の増強を示す。
図5は、マウス脾細胞中の抑制性T細胞のFACS解析の結果を示す。
図6は、Sarcoma180担癌マウス脾臓中におけるGITR陽性抑制性T細胞の割合を示す。
図7は、たもぎ茸熱水抽出物および他のキノコ抽出物を与えたSarcoma180移植マウスの腫瘍体積の変化を示す。
図8は、たもぎ茸熱水抽出物および他のキノコ抽出物を与えたSarcoma180移植マウスの腫瘍重量の平均値を示す。
図9は、たもぎ茸熱水抽出物および他のキノコ抽出物を与えたSarcoma180移植マウスの生存率を示す。
FIG. 1 shows suppression of HeLa cell proliferation by a hot water extract of potato.
FIG. 2 shows the inhibition of tumor cell Sarcoma 180 growth by the hot water extract of taro.
FIG. 3 shows an increase in activated antigen expression of human dendritic cells by the extract of hot water from potato.
FIG. 4 shows the enhancement of IL-12 production from human dendritic cells by a hot water extract of cypress salmon.
FIG. 5 shows the results of FACS analysis of inhibitory T cells in mouse spleen cells.
FIG. 6 shows the ratio of GITR positive inhibitory T cells in the spleen of Sarcoma 180 tumor-bearing mice.
FIG. 7 shows the change in tumor volume of Sarcoma 180-transplanted mice that received a scalloped hot water extract and other mushroom extracts.
FIG. 8 shows the mean value of tumor weight of Sarcoma 180 transplanted mice fed with scalloped hot water extract and other mushroom extracts.
FIG. 9 shows the survival rate of Sarcoma 180-transplanted mice fed with a scallop hot water extract and other mushroom extracts.

たもぎ茸はヒラタケ属に属するキノコであり、北海道を中心として広く食用に供されている。たもぎ茸抽出物は以下の方法によって製造することができる。本発明において使用するたもぎ茸は、天然に産するものを収穫してもよく、工場で人工栽培してもよい。たもぎ茸は、好ましくは、収穫後2時間以内に使用する。   Tamamogi is a mushroom belonging to the genus Oyster mushroom and is widely used for food mainly in Hokkaido. The bamboo shoot extract can be produced by the following method. As for the rice cake used in the present invention, a naturally occurring product may be harvested or artificially cultivated in a factory. The bamboo shoots are preferably used within 2 hours after harvest.

収穫したたもぎ茸から有効成分を抽出する。抽出は好ましくは熱水抽出により行う。例えば、収穫したたもぎ茸を、たもぎ茸の重量の2−30倍、好ましくは5−20倍量の沸騰水の中に投入し、蒸気を加えながら撹拌する。沸騰してから10分間撹拌しながらたもぎ茸エキスを抽出する。得られたエキスはそのまま使用してもよく、濾過して固形分を除いてもよい。また、減圧濃縮機、凍結濃縮機等を用いて適宜濃縮してもよい。また、エキスを長期間保存するためには、レトルトパックに封入した後、例えば、120℃、15分間で殺菌処理をしてもよく、凍結乾燥または噴霧乾燥により粉末としてもよい。   Extract active ingredients from harvested bamboo shoots. The extraction is preferably performed by hot water extraction. For example, the harvested bamboo shoots are put into boiling water of 2-30 times, preferably 5-20 times the weight of the bamboo shoots, and stirred while adding steam. Extract the rice cake extract while stirring for 10 minutes after boiling. The obtained extract may be used as it is, or may be filtered to remove the solid content. Moreover, you may concentrate suitably using a vacuum concentrator, a freeze concentrator, etc. Further, in order to store the extract for a long period of time, after being enclosed in a retort pack, it may be sterilized, for example, at 120 ° C. for 15 minutes, or may be powdered by freeze drying or spray drying.

このようにして得られたたもぎ茸抽出物は、後述の実施例で示されるように、HeLa細胞などのヒト癌に由来する細胞株の増殖を抑制し、マウスに移植した肉腫の成長を阻害することができた。さらに、たもぎ茸抽出物が、IL−12などの免疫賦活性サイトカインの産生を増強し、樹状細胞を活性化させ、免疫抑制性T細胞の出現を阻害しうることが示された。これらの結果は、本発明にしたがうたもぎ茸抽出物が、免疫賦活活性および腫瘍細胞増殖抑制活性を有することを裏付ける。   The rice cake extract thus obtained suppresses the growth of cell lines derived from human cancer such as HeLa cells and inhibits the growth of sarcomas transplanted into mice, as will be shown in Examples described later. We were able to. Furthermore, it has been shown that the extract of rice moth can enhance the production of immunostimulatory cytokines such as IL-12, activate dendritic cells, and inhibit the appearance of immunosuppressive T cells. These results confirm that the extract of eel paste according to the present invention has immunostimulatory activity and tumor cell growth inhibitory activity.

本発明にしたがって得られたたもぎ茸抽出物は、そのまま免疫賦活用健康食品あるいは腫瘍細胞増殖抑制用健康食品として用いることができるが、他の食品に添加して用いてもよい。摂取量は、固形分2.5%のエキスとして0.1−10ml/kg/日、特に1.8−2.7ml/kg/日が適当である。   The bamboo shoot extract obtained according to the present invention can be used as it is as an immune-stimulated health food or a tumor food growth-preventing health food, but may be added to other foods. The intake is suitably 0.1-10 ml / kg / day, especially 1.8-2.7 ml / kg / day, as an extract with a solid content of 2.5%.

本発明にしたがう免疫賦活剤は、毒性を有しないこと、多量に摂取しても生体に悪影響を与えないことなどの利点を有するため、健康食品に添加するのに非常に適している。   The immunostimulant according to the present invention is very suitable for addition to health food because it has advantages such as no toxicity and no adverse effects on the living body even when ingested in large amounts.

本明細書において明示的に引用される全ての特許および参考文献の内容は全て本明細書の一部としてここに引用する。また,本出願が有する優先権主張の基礎となる出願である日本特許出願2004−290528号の明細書および図面に記載の内容は全て本明細書の一部としてここに引用する。   The contents of all patents and references explicitly cited herein are hereby incorporated by reference as part of the present specification. In addition, the contents described in the specification and drawings of Japanese Patent Application No. 2004-290528, which is the application on which the priority of the present application is based, are cited herein as a part of this specification.

以下に実施例により本発明をより詳細に説明するが、本発明はこれらの実施例により限定されるものではない。   EXAMPLES The present invention will be described below in more detail with reference to examples, but the present invention is not limited to these examples.

キノコ熱水抽出物の調製
各種キノコの熱水抽出物を調製した。たもぎ茸、マイタケ、シメジ、およびシイタケ各1kgをそれぞれ沸騰水5kg中に入れ、さらに加熱し、沸騰してから10分間撹拌した。得られた抽出液を減圧濃縮して、固形分2.5%の濃縮物240mlを得た。得られた濃縮物を120℃、15分間のレトルト殺菌処理をして、キノコ熱水抽出物を得た。
Preparation of Mushroom Hot Water Extract Hot water extracts of various mushrooms were prepared. Each 1 kg of tamago mushroom, maitake mushroom, shimeji mushroom and shiitake mushroom was placed in 5 kg of boiling water, further heated, and stirred for 10 minutes after boiling. The obtained extract was concentrated under reduced pressure to obtain 240 ml of a 2.5% solid concentrate. The obtained concentrate was subjected to a retort sterilization treatment at 120 ° C. for 15 minutes to obtain a mushroom hot water extract.

HeLa細胞増殖抑制活性
実施例1で製造したたもぎ茸熱水抽出物をさらに減圧濃縮して、3倍濃度のたもぎ茸エキスを調製し、これを用いて、HeLa細胞増殖抑制活性を測定した。HeLa細胞を96穴マイクロプレートでMEM培地中に3.7x10細胞/ウエルで播種し、たもぎ茸エキスを最終固形分濃度がそれぞれ1.25%、2.5%、2.75%および3.75%となるようにウエルに加え、37℃で培養した。12、24、および48時間後に、MTT法により450nmで細胞数を係数した。
HeLa cell growth inhibitory activity The bamboo shoot hot water extract produced in Example 1 was further concentrated under reduced pressure to prepare a 3-fold concentration of bamboo shoot extract, which was used to measure the HeLa cell growth inhibitory activity. . HeLa cells were seeded in a 96-well microplate in MEM medium at 3.7 × 10 3 cells / well, and the rice cake extract had final solids concentrations of 1.25%, 2.5%, 2.75% and 3 respectively. .75% was added to the wells and cultured at 37 ° C. After 12, 24, and 48 hours, the cell number was factored at 450 nm by the MTT method.

結果を図1に示す。たもぎ茸エキス添加後12時間および24時間では、すべての濃度で細胞数が減少した。48時間では2.5%濃度以上で細胞数の減少が見られた。すなわち、たもぎ茸エキスを添加することによりHeLa細胞の増殖が抑制されることが明らかとなった。なお、対照としてマウス脾臓由来の正常細胞についても同様の実験を行ったが、たもぎ茸エキスは正常細胞の増殖には影響を及ぼさなかった。   The results are shown in FIG. At 12 and 24 hours after the addition of the bamboo shoot extract, the number of cells decreased at all concentrations. In 48 hours, a decrease in the number of cells was observed at a concentration of 2.5% or more. That is, it was revealed that the growth of HeLa cells was suppressed by adding the bamboo shoot extract. As a control, the same experiment was performed on normal cells derived from the mouse spleen, but the rice cake extract did not affect the growth of normal cells.

肉腫に対する抗腫瘍効果
実施例1で製造したたもぎ茸熱水抽出物のSarcoma180に対する抗腫瘍効果を測定した。Sarcoma180の凍結細胞(東北大学加齢医学研究所より入手)を、37℃の温水で急速解凍し、約10倍量の生理食塩水を加え、遠心分離(1000回転/分、5分間)し、上清を除去した。この操作を4回繰り返した後、ペレットに約3倍量の生理食塩水を加えて撹拌し、細胞液とした。
Anti-tumor effect on sarcoma The anti-tumor effect on Sarcoma 180 of the extract of hot water of hot water produced in Example 1 was measured. Sarcoma 180 frozen cells (obtained from Tohoku University Institute for Aging Medicine) are rapidly thawed with warm water at 37 ° C., added with about 10 times the amount of physiological saline, and centrifuged (1000 rpm / min, 5 minutes). The supernatant was removed. After repeating this operation four times, about 3 times the amount of physiological saline was added to the pellet and stirred to obtain a cell solution.

細胞液0.1ml(約5×10個の細胞)を雌マウス(Slc:ICR)5匹の腹腔内に移植し、7日後に頸椎脱臼により犠牲死させた。腹部をエタノール消毒し、滅菌した注射筒を用いて腹水を回収した。各動物から回収した腹水を混合し、約5×10個の細胞を雌マウス(Slc:ICR、5週齢、約18g)の鼡径部皮下に移植した。0.1 ml of cell solution (about 5 × 10 6 cells) was transplanted into the abdominal cavity of 5 female mice (Slc: ICR), and sacrificed by cervical dislocation 7 days later. The abdomen was disinfected with ethanol, and ascites was collected using a sterilized syringe. Ascites collected from each animal was mixed, and about 5 × 10 6 cells were transplanted subcutaneously into the groin of a female mouse (Slc: ICR, 5 weeks old, about 18 g).

予防効果の評価実験(群1−3)においては腫瘍移植前10日間および移植後21日間、治療効果の評価実験(群4)においては移植後21日間、それぞれ1日1回試験溶液を経口投与した。投与は、所定量のたもぎ茸熱水抽出物と精製水からなる試験溶液12ml/kgをマウス用金属ゾンデを用いて移植動物の胃内に強制的に投与することにより行った。投与量は以下の表に示すとおりである。   Oral administration of the test solution once a day for 10 days before tumor transplantation and 21 days after transplantation in the evaluation experiment (group 1-3) for prevention effect, and 21 days after transplantation for the evaluation experiment (group 4) for treatment effect did. The administration was performed by forcibly administering a predetermined amount of 12 ml / kg of a test solution consisting of hot water extract of hot water and purified water into the stomach of the transplanted animal using a metal sonde for mice. The dosage is as shown in the table below.

Figure 2006038527
Figure 2006038527

移植後5、7、10、14、17、21および22日目に腫瘍体積を測定した。腫瘍体積は、ノギスを用いて腫瘍の短径(a)および長径(b)を測定し、以下の式により算出し、平均±標準偏差で示した。
腫瘍体積(cm)=4/3πab/2
Tumor volumes were measured on days 5, 7, 10, 14, 17, 21, and 22 after transplantation. The tumor volume was measured by measuring the short axis (a) and the long axis (b) of the tumor using a caliper, calculated by the following formula, and indicated as mean ± standard deviation.
Tumor volume (cm 3 ) = 4 / 3πa 2 b / 2

結果を図2に示す。たもぎ茸熱水抽出物を投与することにより、腫瘍体積の増加が有意に抑制されることが示された。また、たもぎ茸熱水抽出物を予防的に投与することにより、さらに高い効果が得られることがわかった。   The results are shown in FIG. It was shown that the increase in tumor volume was significantly suppressed by administration of the hot water extract of Tamogi. In addition, it was found that a higher effect can be obtained by prophylactic administration of the extract of hot water of Tamogi.

樹状細胞の細胞表面抗原の発現変化
ヒト末梢血単核球由来樹状細胞の誘導は、加藤ら(K. Kato, et al., J Leukoc Biol, 70: 941-949, 2001)に記載されている手法に従い調製した。まず、ヘパリンを加えたシリンジを用いて健常人左腕静脈部より血液15−20mlを採取し、無菌下で等量のPBSで希釈した。等倍希釈血液を予め無菌プラスチックチューブに準備したリンフォセパール15ml(IBL社製)上に重層し、1500rpmで30分間遠心分離した。遠心後、リンフォセパール上の単核球層を回収し、PBSにて細胞を2回遠心洗浄した。単核球は最終的にRPMI1640培地、10%ウシ胎児血清含(Sigma社製)に希釈し、10cmのプラスチックシャーレに細胞を添加し培養した。37℃で30分後に非付着性の細胞(リンパ球)を除去し、付着細胞(単核球)に対して樹状細胞誘導培地(RPMI1640培地、10%ウシ胎児血清、50ng/mlヒトGM−CSF(オステオジェネティクス社製)および50ng/mlヒトIL−4(オステオジェネティクス社製))にて37℃で7日間培養し、ヒト単核球由来樹状細胞を誘導した。
Altered expression of cell surface antigens of dendritic cells The induction of dendritic cells derived from human peripheral blood mononuclear cells is described in Kato et al. (K. Kato, et al., J Leukoc Biol, 70: 941-949, 2001). Prepared according to the procedure. First, 15-20 ml of blood was collected from the left arm vein of a healthy person using a syringe with heparin added, and diluted with an equal volume of PBS under aseptic conditions. The same-diluted blood was layered on 15 ml of Lymphosepar (manufactured by IBL) prepared in advance in a sterile plastic tube, and centrifuged at 1500 rpm for 30 minutes. After centrifugation, the mononuclear cell layer on Lymphosepar was recovered, and the cells were washed twice by centrifugation with PBS. The mononuclear cells were finally diluted in RPMI 1640 medium containing 10% fetal calf serum (manufactured by Sigma), and the cells were added to a 10 cm plastic petri dish and cultured. After 30 minutes at 37 ° C., non-adherent cells (lymphocytes) were removed, and dendritic cell induction medium (RPMI 1640 medium, 10% fetal calf serum, 50 ng / ml human GM- Cultured with CSF (manufactured by Osteogenetics) and 50 ng / ml human IL-4 (manufactured by Osteogenetics) for 7 days at 37 ° C., human mononuclear cell-derived dendritic cells were induced.

誘導した樹状細胞をプラスチックチューブに回収し、RPMI1640培地を加えて遠心洗浄を行い、細胞数を測定した。細胞濃度を最終的に2x10個/mlにRPMI1640培地で調整し、0.5mlずつ24穴プレートに添加し、実施例1で調製した各種キノコ熱水抽出液(たもぎ茸、マイタケ、シメジ、シイタケ)をそれぞれ最終濃度2%で添加し37℃で24時間培養した。The induced dendritic cells were collected in a plastic tube, RPMI1640 medium was added, centrifugal washing was performed, and the number of cells was measured. The cell concentration was finally adjusted to 2 × 10 5 cells / ml with RPMI 1640 medium, 0.5 ml each was added to the 24-well plate, and various mushroom hot water extracts prepared in Example 1 (Tamogi mushroom, maitake, shimeji mushroom, Shiitake) was added at a final concentration of 2% and cultured at 37 ° C for 24 hours.

キノコ熱水抽出液で刺激した樹状細胞をプラスチックチューブに回収し、RPMI1640培地で遠心洗浄後、FITC標識抗ヒトCD45抗体、PE標識抗ヒトCD86抗体(いずれもeBioscience社製)を各5μl添加し、4℃で1時間反応後、FACS(BD社製)にて細胞表面抗原の発現変化を解析した。樹状細胞におけるCD54およびCD86は、免疫応答の惹起に不可欠な分子であり、抗原発現の増加は樹状細胞の活性化状態を示すものであることが知られている。その結果、図3に示すようにたもぎ茸熱水抽出液を添加した樹状細胞において非添加細胞と比較してCD86抗原の発現増加(ヒストグラムの右側へのシフト)が確認された。またこの発現増強は他のキノコ抽出液(マイタケ、シメジ)ではほとんど認められなかった。下記の表に樹状細胞上のCD54抗原とCD86抗原の発現変化量を示す(FlowJoソフトによる解析;TreeStar社製)。   Dendritic cells stimulated with mushroom hot water extract are collected in a plastic tube, centrifuged after washing with RPMI1640 medium, and 5 μl each of FITC-labeled anti-human CD45 antibody and PE-labeled anti-human CD86 antibody (both manufactured by eBioscience) are added. After reaction at 4 ° C. for 1 hour, changes in the expression of cell surface antigens were analyzed by FACS (BD). CD54 and CD86 in dendritic cells are molecules essential for eliciting an immune response, and it is known that an increase in antigen expression indicates an activated state of dendritic cells. As a result, as shown in FIG. 3, an increase in the expression of CD86 antigen (shift to the right side of the histogram) was confirmed in dendritic cells to which the hot water extract of paddy rice was added as compared to non-added cells. This enhanced expression was hardly observed in other mushroom extracts (maitake, shimeji). The following table shows changes in the expression of CD54 antigen and CD86 antigen on dendritic cells (analysis with FlowJo software; manufactured by TreeStar).

Figure 2006038527
たもぎ茸熱水抽出液を添加することにより樹状細胞のCD54、CD86抗原の発現が増加していることが確認され、この効果は他のキノコよりも有意に高いものであった。
Figure 2006038527
It was confirmed that the expression of CD54 and CD86 antigens in dendritic cells was increased by adding the hot water extract of Tamogi, and this effect was significantly higher than that of other mushrooms.

樹状細胞からのIL−12産生
実施例1で製造した各種キノコ熱水抽出物を用いて、ヒト樹状細胞からのIL−12産生の増強効果を調べた。インターロイキン12(IL−12)は、主として樹状細胞から産生されるサイトカインの1種であり、NK細胞、Th1細胞の活性化に最も重要な因子であることが知られている。活性化樹状細胞から産生されるインターロイキン12(IL−12)の産生増強効果は以下の方法にて解析した。実施例4と同様に誘導した樹状細胞を細胞濃度を最終的に2x10個/mlにRPMI1640培地で調整し、0.5mlずつ24穴プレートに添加した。成熟化刺激としては、アデノウイルスによるCD40リガンド遺伝子導入(AxCACD40L−F/RGD、300粒子/細胞)を行い、さらに各種キノコ熱水抽出物(たもぎ茸、マイタケ、シメジ、シイタケ)をそれぞれ最終濃度2%で添加し37℃で48時間培養した。
IL-12 production from dendritic cells Using the various mushroom hot water extracts produced in Example 1, the effect of enhancing IL-12 production from human dendritic cells was examined. Interleukin 12 (IL-12) is one of cytokines mainly produced from dendritic cells, and is known to be the most important factor for activation of NK cells and Th1 cells. The production enhancing effect of interleukin 12 (IL-12) produced from activated dendritic cells was analyzed by the following method. Dendritic cells induced in the same manner as in Example 4 were finally adjusted to a cell concentration of 2 × 10 5 cells / ml with RPMI 1640 medium, and 0.5 ml each was added to a 24-well plate. For maturation stimulation, CD40 ligand gene introduction by adenovirus (AxCACD40L-F / RGD, 300 particles / cell) was performed, and various mushroom hot water extracts (Tamogi salmon, maitake, shimeji, shiitake) were each at final concentrations. It was added at 2% and cultured at 37 ° C for 48 hours.

キノコ熱水抽出液で48時間活性化刺激した樹状細胞の培養液をプラスチックチューブに回収し、10000rpm、5分間遠心して上清を回収した。培養上清をPBSにて10倍に希釈後、IL−12含有量をELISAキット(R&D社製)を用いて測定した。その結果、キノコ熱水抽出液を添加していない樹状細胞では13.0±0.1ng/mlの産生に対して、たもぎ茸熱水抽出液添加樹状細胞では14.4±0.1ng/mlと有意な差をもってIL−12の産生が亢進していた。またこの効果は他のキノコ(シイタケ:13.8±0.1ng/mlよりも高いものであった。   The culture solution of dendritic cells stimulated with mushroom hot water extract for 48 hours was collected in a plastic tube and centrifuged at 10,000 rpm for 5 minutes to collect the supernatant. The culture supernatant was diluted 10 times with PBS, and then the IL-12 content was measured using an ELISA kit (R & D). As a result, dendritic cells to which mushroom hot water extract was not added produced 13.0 ± 0.1 ng / ml, whereas 14.4 ± 0. IL-12 production was enhanced with a significant difference from 1 ng / ml. This effect was higher than that of other mushrooms (Shiitake: 13.8 ± 0.1 ng / ml).

脾細胞中の抑制性T細胞の解析
実験動物はSlc:ICR系のSPF雄性マウス(日本エスエルシー株式会社)より購入した生後5週齢の動物を飼育室で1週間飼育を行った後に実験を開始した。飼育室の平均温度は22℃、湿度50%の空調施設にて、無菌ケージ内で固形飼料を自由摂取で飼育した。ICRマウスの大腿部皮下に実施例3で示したSarcoma180細胞を1匹あたり500万個の細胞数を1ml注射筒と注射針26G(テルモ)を用いて投与した。
Analysis of inhibitory T cells in spleen cells Experimental animals were tested after 5 weeks old animals purchased from Slc: ICR male SPF mice (Japan SLC Co., Ltd.) were kept in a breeding room for 1 week. Started. The average temperature of the breeding room was 22 ° C. and the humidity was 50%. Sarcoma 180 cells shown in Example 3 were administered subcutaneously to the thigh of an ICR mouse at the number of 5 million cells per mouse using a 1 ml syringe and an injection needle 26G (Terumo).

移植同日に実施例1で製造した被験物質たもぎ茸抽出物をマウス用金属ゾンデにて胃内に強制的に4ml/kgを連日21日目まで投与した。対照群として生理食塩水(大塚製薬(株))を等量投与した。1群あたりマウスは7匹使用した。移植後より週2回継続的に腫瘍系を測定し、21日後まで腫瘍体積を測定したところ、たもぎ茸熱水抽出物投与群で有為な腫瘍増殖抑制効果が認められた。この結果は実施例3で示した増殖抑制と同様であり、抗腫瘍効果が再確認された。   On the same day of transplantation, 4 ml / kg of the test substance tofu mushroom extract prepared in Example 1 was forcibly administered into the stomach with a mouse metal sonde until the 21st day of each day. As a control group, an equal amount of physiological saline (Otsuka Pharmaceutical Co., Ltd.) was administered. Seven mice were used per group. The tumor system was measured twice a week after the transplantation, and the tumor volume was measured until 21 days later. As a result, a significant tumor growth inhibitory effect was observed in the group treated with the hot water extract. This result was the same as the growth inhibition shown in Example 3, and the antitumor effect was reconfirmed.

腫瘍移植後22日目に全ての腫瘍移植マウスを深麻酔下にて安楽死後、脾臓を腹腔内から摘出した。摘出脾臓を培養液の満たされたシャーレ内でほぐしてリンパ球を主体とした脾細胞液を得た。得られた脾臓細胞中の赤血球を溶血後、細胞数を測定しプラスチックチューブに10万個の細胞を入れた。   On day 22 after tumor transplantation, all tumor-transplanted mice were euthanized under deep anesthesia, and the spleen was removed from the abdominal cavity. The isolated spleen was loosened in a petri dish filled with a culture solution to obtain a spleen cell solution mainly composed of lymphocytes. After hemolysis of erythrocytes in the obtained spleen cells, the number of cells was measured and 100,000 cells were put into a plastic tube.

脾臓は腫瘍系が大きいほど巨大化しており、繊維芽質でやや赤みが薄く、骨髄系の細胞の混入も多く認められた。たもぎ茸熱水抽出物投与マウスでは生理食塩水投与マウスに比べて脾臓の巨大化、繊維芽質の程度も軽度であった。   The larger the tumor line, the larger the spleen was, the fibroblasts were slightly reddish, and many myeloid cell contamination was observed. In mice treated with hot water extract of Tamogi, the spleen was enlarged and the degree of fibroblast was milder than that in mice treated with physiological saline.

脾細胞中の抑制性T細胞の蛍光染色は以下に示すとおりに行った。各投与群7匹で実施したが、抑制性T細胞の解析はうち6匹を用いて施行した。各マウスの実験番号は以下の通りである。
グループ1:生理食塩水投与群
151、152、153、154、155、157
グループ2:タモギタケ熱水抽出液投与群
251、252、254、255、256、257
Fluorescent staining of inhibitory T cells in splenocytes was performed as shown below. Although it carried out by each administration group 7 animals, the analysis of the inhibitory T cell was enforced using 6 of them. The experiment number of each mouse is as follows.
Group 1: Saline administration group 151, 152, 153, 154, 155, 157
Group 2: Tamogitake hot water extract administration group 251, 252, 254, 255, 256, 257

各細胞入りのプラスチックチューブにFITC-CD4 (RM4-5; 0.5μl/reaction, eBioscience), Biotin-GITR (DTA-1; 0.5μl/reaction, eBioscience), Avidine-PE (0.2μl/reaction, BDpharmingen)を添加し、4℃で1時間反応させた。PBSで細胞を洗浄後PI染色にて死細胞を除去し、FACScalibur(BDバイオサイエンス社製)を用いて蛍光標識細胞を測定した。抑制性T細胞数の解析はFlowJoソフトウェア(トリースター社製)を用いて解析した。   FITC-CD4 (RM4-5; 0.5μl / reaction, eBioscience), Biotin-GITR (DTA-1; 0.5μl / reaction, eBioscience), Avidine-PE (0.2μl / reaction, BDpharmingen) Was added and reacted at 4 ° C. for 1 hour. After washing the cells with PBS, dead cells were removed by PI staining, and fluorescence-labeled cells were measured using FACScalibur (BD Bioscience). The number of suppressor T cells was analyzed using FlowJo software (manufactured by Torystar).

抑制性T細胞はCD4陽性T細胞(FITC陽性細胞)中のGITR陽性細胞を割合で算出した。その結果を図5および6に示す。GITR陽性抑制性T細胞は、たもぎ茸熱水抽出物投与担癌マウス群 (13.2%±3.1%) では生理食塩水投与担癌マウス(33.4%±10.6%) にくらべて有為に減少していることが判明した。   Inhibitory T cells were calculated as a percentage of GITR positive cells in CD4 positive T cells (FITC positive cells). The results are shown in FIGS. GITR-positive inhibitory T cells were significantly decreased in the tumor-bearing mice group (13.2% ± 3.1%) treated with the extract of hot water extract compared to the tumor-bearing mice (33.4% ± 10.6%) administered with saline. Turned out to be.

以上の結果から、たもぎ茸熱水抽出物には、担癌状態により誘導される免疫抑制性T細胞の出現を阻害できる活性物質が含まれることが示された。このことは、たもぎ茸抽出物が免疫賦活剤として有用であることを示す。   From the above results, it was shown that the hot water extract of Tamogi soak contains an active substance that can inhibit the appearance of immunosuppressive T cells induced by the cancer-bearing state. This indicates that the bamboo shoot extract is useful as an immunostimulator.

肉腫に対する予防的抗腫瘍効果の比較
たもぎ茸熱水抽出物および市販のキノコ抽出物のSarcoma180に対する予防的抗腫瘍効果を測定した。被検物質としては、実施例1で製造したたもぎ茸熱水抽出物(ロット1および2)、アガリクス仙生露ロイヤルおよびメシマ(登録商標)ピュアPL2.5を使用した。
Comparison of prophylactic anti-tumor effect against sarcoma The prophylactic anti-tumor effect of Sorghum hot water extract and commercial mushroom extract against Sarcoma 180 was measured. As a test substance, the hot water extract of hot water (produced in Example 1) (lots 1 and 2), Agaricus Sengyo-ro Royal and Meshima (registered trademark) Pure PL2.5 were used.

Sarcoma180の凍結細胞(TKG0173、東北大学加齢医学研究所より入手)を、37℃の温水で急速解凍し、約10倍量の生理食塩水を加え、遠心分離(1000回転/分、5分間)し、上清を除去した。この操作を4回繰り返した後、ペレットに約3倍量の生理食塩水を加えて撹拌し、細胞液とした。細胞液0.1ml(約5×10個の細胞)をマウスの腹腔内に移植し、7日後に頸椎脱臼により犠牲死させた。腹部をエタノール消毒し、滅菌した注射筒を用いて腹水を回収した。各動物から回収した腹水を混合し、約5×10個の細胞を試験動物の鼡径部皮下に移植した。Sarcoma 180 frozen cells (TKG0173, obtained from Tohoku University Institute of Aging Medicine) are rapidly thawed with 37 ° C. warm water, added with about 10 times the amount of physiological saline, and centrifuged (1000 rpm / minute, 5 minutes). And the supernatant was removed. After repeating this operation four times, about 3 times the amount of physiological saline was added to the pellet and stirred to obtain a cell solution. 0.1 ml of cell solution (about 5 × 10 6 cells) was transplanted into the abdominal cavity of the mouse and sacrificed by cervical dislocation 7 days later. The abdomen was disinfected with ethanol, and ascites was collected using a sterilized syringe. Ascites collected from each animal was mixed and about 5 × 10 6 cells were transplanted subcutaneously into the groin area of the test animal.

試験動物としては6週齢の雌マウス(Slc:ICR)を各群10匹ずつ用い、飼料および水を自由に摂取させた。腫瘍移植前10日間および移植後35日間、1日1回試験溶液を経口投与した。投与は、所定量のたもぎ茸熱水抽出物または対照キノコ抽出物と精製水からなる試験溶液12ml/kgをマウス用金属ゾンデを用いて移植動物の胃内に強制的に投与することにより行った。投与量は以下の表に示すとおりである。   As test animals, 6-week-old female mice (Slc: ICR) were used, 10 per group, and food and water were freely fed. The test solution was orally administered once a day for 10 days before tumor transplantation and 35 days after transplantation. Administration is carried out by forcibly administering a predetermined amount of 12 ml / kg test solution consisting of hot water extract or control mushroom extract and purified water into the stomach of transplanted animals using a mouse metal sonde. It was. The dosage is as shown in the table below.

Figure 2006038527
Figure 2006038527

腫瘍体積は、実験開始日、移植後5、7、10、14、17、21、24、28、32および36日目(観察終了日)に、生存している個体について測定した。腫瘍体積は、ノギスを用いて腫瘍の短径(a)および長径(b)を測定し、以下の式により算出した。
腫瘍体積(cm)=4/3πab/2
Tumor volume was measured on surviving individuals on the day of experiment, 5, 7, 10, 14, 17, 21, 24, 28, 32 and 36 (end of observation) after transplantation. The tumor volume was calculated by the following formula after measuring the minor axis (a) and major axis (b) of the tumor using calipers.
Tumor volume (cm 3 ) = 4 / 3πa 2 b / 2

腫瘍重量は、死亡例は発見後速やかに、生存例は最終投与(移植後35日目)の翌日に測定した。試験動物をエーテル麻酔下で放血により安楽死させ、左鼠径部の腫瘍を摘出し、その重量を測定した。各試験群の腫瘍重量の平均値より、それぞれの腫瘍増殖阻止率を以下の式により算出した。
腫瘍増殖阻止率(%)=(1−投与群の平均腫瘍重量/対照群の平均腫瘍重量)×100
Tumor weight was measured immediately after discovery for dead cases, and the day after the final administration (35 days after transplantation) for surviving cases. The test animal was euthanized by exsanguination under ether anesthesia, the tumor of the left inguinal region was removed, and its weight was measured. From the average value of the tumor weight of each test group, each tumor growth inhibition rate was calculated by the following formula.
Tumor growth inhibition rate (%) = (1−average tumor weight of administration group / average tumor weight of control group) × 100

延命率は、腫瘍移植後の試験動物の生存日数を調べ、以下の式により算出した。
延命率(%)=(投与群の平均生存日数/対照群の平均生存日数−1)×100
The survival rate was calculated by the following formula after examining the survival days of test animals after tumor transplantation.
Survival rate (%) = (average survival days of administration group / average survival days of control group−1) × 100

各パラメータについて一元配置分散分析を実施し(有意水準10%)、群間に有意差がみられた場合は、平均値についてDunnettの多重比較検定を実施した(有意水準5%および1%)。   A one-way analysis of variance was performed for each parameter (significance level 10%), and if there was a significant difference between groups, Dunnett's multiple comparison test was performed on the mean values (significance levels 5% and 1%).

結果を図7−9に示す。たもぎ茸熱水抽出物投与群では、腫瘍体積の平均値は経日的に増加したが対照群より低値で推移し、移植後5日目以降では、対照群と比較して統計学的に有意に低い値を示した。腫瘍重量の平均値は対照群と比べて23.4−29.3%の腫瘍増殖抑制が認められたが、統計学的有意差はみられなかった。延命率は15.5−21.0%であった。また、生存日数において対照群と比べ統計学的に有意な延命効果がみられた。   The results are shown in FIGS. 7-9. In the Tamogi hot water extract administration group, the mean value of the tumor volume increased daily, but remained at a lower value than that in the control group. The value was significantly lower. The average value of tumor weight was 23.4-29.3% tumor growth suppression compared to the control group, but no statistically significant difference was observed. The life extension rate was 15.5-21.0%. In addition, the survival time was statistically significant compared to the control group.

アガリクス投与群では、腫瘍体積の平均値は経日的に増加したが対照群より低値で推移し、移植後5日目以降断続的に、対照群と比較して統計学的に有意に低い値を示した。腫瘍重量の平均値は対照群と比べて5.7%の腫瘍増殖抑制が認められたが、統計学的有意差はみられなかった。延命率は20.6%であった。また、生存日数において対照群と比べ統計学的に有意な延命効果がみられた。メシマ(登録商標)投与群では、腫瘍体積の平均値は経日的に増加したが対照群より低値で推移し、移植後5日目以降断続的に、対照群と比較して統計学的に有意に低い値を示した。腫瘍重量の平均値は対照群と比べて24.6%の腫瘍増殖抑制が認められたが、統計学的有意差はみられなかった。延命率は8.9%であった。また、生存日数は対照群と比べ統計学的有意差はみられなかった。   In the Agaricus-administered group, the mean value of tumor volume increased daily, but remained at a lower value than the control group, and was statistically significantly lower than the control group intermittently after the fifth day after transplantation. The value is shown. The average value of tumor weight was 5.7% of tumor growth suppression compared to the control group, but no statistically significant difference was observed. The life extension rate was 20.6%. In addition, the survival time was statistically significant compared to the control group. In the Mesima (registered trademark) administration group, the mean value of the tumor volume increased with time, but remained at a lower value than the control group, and statistically compared with the control group intermittently after the fifth day after transplantation. The value was significantly lower. The average value of tumor weight was 24.6% of tumor growth suppression compared to the control group, but no statistically significant difference was observed. The life extension rate was 8.9%. In addition, the survival days did not show a statistically significant difference compared with the control group.

以上のことから、たもぎ茸熱水抽出物を予防的に投与することにより、腫瘍増殖抑制効果および延命効果が認められた。   Based on the above, tumor growth inhibitory effects and life-prolonging effects were recognized by prophylactic administration of the extract of hot water from potatoes.

本発明の抗腫瘍性免疫賦活剤は腫瘍細胞の増殖の抑制に有用である。   The antitumor immunostimulatory agent of the present invention is useful for suppressing the growth of tumor cells.

Claims (10)

たもぎ茸抽出物を有効成分とする抗腫瘍性免疫賦活剤。 An anti-tumor immunostimulant comprising a potato extract as an active ingredient. たもぎ茸抽出物を有効成分とする腫瘍細胞増殖抑制剤。 A tumor cell growth inhibitor comprising tarogi extract as an active ingredient. たもぎ茸抽出物を有効成分とする免疫賦活性サイトカインの産生増強剤。 An agent that enhances the production of immunostimulatory cytokines, comprising a potato extract as an active ingredient. たもぎ茸抽出物を有効成分とする免疫抑制性T細胞増加の抑制剤。 An inhibitor of an increase in immunosuppressive T cells, which comprises an extract of tarogi. たもぎ茸抽出物からなる免疫賦活用健康食品。 An immune-stimulated health food made from bamboo shoot extract. たもぎ茸抽出物からなる腫瘍細胞増殖抑制用健康食品。 A health food for suppressing tumor cell growth comprising an extract of bamboo shoots. たもぎ茸抽出物を被験者に投与することにより、被験者において抗腫瘍性免疫を賦活させる方法。 A method of stimulating anti-tumor immunity in a subject by administering the potato extract to the subject. たもぎ茸抽出物を被験者に投与することにより、被験者において腫瘍細胞の増殖を抑制する方法。 A method for inhibiting the growth of tumor cells in a subject by administering the potato paste extract to the subject. たもぎ茸抽出物を被験者に投与することにより、免疫賦活性サイトカインの産生を増強する方法。 A method of enhancing the production of immunostimulatory cytokines by administering a potato extract to a subject. たもぎ茸抽出物を被験者に投与することにより、免疫抑制性T細胞増加を抑制する方法。 A method for suppressing an increase in immunosuppressive T cells by administering a potato paste extract to a subject.
JP2006539248A 2004-10-01 2005-09-29 Anti-tumor immunostimulant containing tamogi mushroom extract as active ingredient Withdrawn JPWO2006038527A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004290528 2004-10-01
JP2004290528 2004-10-01
PCT/JP2005/018004 WO2006038527A1 (en) 2004-10-01 2005-09-29 Antitumor immunostimulant containing extract from pleurotus cornucopiae as active ingredient

Publications (1)

Publication Number Publication Date
JPWO2006038527A1 true JPWO2006038527A1 (en) 2008-05-15

Family

ID=36142603

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539248A Withdrawn JPWO2006038527A1 (en) 2004-10-01 2005-09-29 Anti-tumor immunostimulant containing tamogi mushroom extract as active ingredient

Country Status (2)

Country Link
JP (1) JPWO2006038527A1 (en)
WO (1) WO2006038527A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4831711B1 (en) * 2010-09-11 2011-12-07 株式会社スリービー Anti-Candida fungi and prophylactic and / or therapeutic agents for candidiasis comprising Tamogitake extract as an active ingredient
JP6121597B1 (en) * 2016-06-09 2017-04-26 株式会社スリービー Immune response activated cytokine production promoter and Th17 cell differentiation promoter
WO2022230493A1 (en) * 2021-04-26 2022-11-03 サントリーホールディングス株式会社 Composition for increasing leukocytes and/or basophils

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3195916B2 (en) * 1993-09-02 2001-08-06 株式会社雪国まいたけ Agent for suppressing or increasing the number of helper T cells in AIDS
JPH11315096A (en) * 1997-08-08 1999-11-16 New Food Creation Gijutsu Kenkyu Kumiai Antitumoral protein derived from pleurotus cornucopiae and its gene
JPWO2003030938A1 (en) * 2001-10-09 2005-01-20 株式会社オリエントキャンサーセラピー Cancer immunotherapy
JP2004020487A (en) * 2002-06-19 2004-01-22 Orient Cancer Therary:Kk Method of inspecting cancer
JP4451100B2 (en) * 2003-08-27 2010-04-14 アピ株式会社 Immunostimulant and anticancer agent containing Tamogitake fruit body composition as active ingredient

Also Published As

Publication number Publication date
WO2006038527A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
WO2015156339A1 (en) Immune balance adjustment agent
Shahbazi et al. Immunostimulants: types and functions
JP2011093928A (en) Fraction obtained from leaf and stem of genus panax having anticancer and antimetastatic activity
Biedron et al. Agaricus blazei Murill-immunomodulatory properties and health benefits
WO2016127847A1 (en) Application of chlorogenic acid in preparing medicines for treating melanoma and medicines for treating melanoma
US10967017B2 (en) Traditional Chinese medicine composition and use thereof
CN105017438B (en) A kind of Radix et Rhizoma Gynurae divaricatae polysaccharide and its application in preparing for immunological regulation and anti-tumor drug and functional food
Jain et al. Immunostimulants: concepts, types and functions
JPWO2006038527A1 (en) Anti-tumor immunostimulant containing tamogi mushroom extract as active ingredient
US11026988B2 (en) Traditional Chinese medicine composition and use thereof
JP5578599B2 (en) Th1 immune function enhancer
US20120003262A1 (en) Anticancer health food containing phellinus linteus and vegetable worms
KR101429379B1 (en) Use of Composition for Dendritic Cell Activation Comprising Pueraria lobata Polysaccharide
CN103013915B (en) Preparation method of high-activity antigen-loaded dendritic cell
Yap et al. The medicinal benefits of lentinan (β-1, 3-D glucan) from Lentinus edodes (Berk.) Singer (shiitake mushroom) through oral administration
Sakaguchi et al. Augmentation of cytolytic activity in murine natural killer cells and inhibition of tumor growth by the ethanol fraction of oyster extract
JP4448330B2 (en) Matsutake-derived anion exchange resin adsorbed fraction, immune enhancer, and stress load recovery accelerator
CN105412155B (en) Trichoderma pseudokoningii exocellular polysaccharide treats and prevents the application of colon cancer and its is combined the application of chemotherapeutic drug therapy colon cancer
JP2019031470A (en) Antitumor composition containing nk cell conditioned medium and method for producing the same
CN105012366B (en) A kind of bright moon grass polysaccharide and its application in preparing for immunological regulation and anti-tumor drug and functional food
TWI245636B (en) gamma delta T cell immunoactivity enhancers containing extract of Lentinus edodes mycelium
Shih et al. The stimulating effects of polyphenol and protein fractions from jelly fig (Ficus awkeotsang Makino) achenes against proliferation of leukemia cells
CN112138018A (en) Application of dendrobium officinale polysaccharide in preparation of medicine for treating tumors by targeting tumor-related macrophages
JP4308350B2 (en) LAK activity screening substance containing shiitake mycelium extract and LAK activity screening method using the same
Ooi et al. Immunomodulatory, antioxidant, antiangiogenic, and antiproliferative effects of rice bran arabinoxylan

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20081202